Calidi Biotherapeutics' Genetic Medicine Platform Highlighted for Potential Cancer Breakthrough

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has garnered attention for its innovative precision genetic medicine platform, as highlighted in a recent editorial. The platform's approach to using engineered viruses to target both primary and metastatic cancer tumors comes at a critical time, with global cancer diagnoses projected to soar to 35 million annually by 2050. This technology represents a significant advancement in the field of oncology, offering a novel method to deliver potent genetic therapies directly to cancer sites. The potential of Calidi's platform to address unmet needs in cancer treatment underscores its importance in the ongoing battle against the disease. For more details on this development, visit https://ibn.fm/GZS7L.